financetom
Business
financetom
/
Business
/
Uber Technologies Q2 Earnings, Revenue Increase; Announces $20 Billion Share Buyback Authorization
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Uber Technologies Q2 Earnings, Revenue Increase; Announces $20 Billion Share Buyback Authorization
Aug 6, 2025 4:34 AM

07:09 AM EDT, 08/06/2025 (MT Newswires) -- Uber Technologies ( UBER ) reported Q2 earnings Wednesday of $0.63 per diluted share, up from $0.47 a year earlier.

Analysts polled by FactSet expected $0.63 per share.

Revenue for the quarter ended June 30 was $12.65 billion, compared with $10.70 billion a year earlier.

Analysts surveyed by FactSet expected $12.47 billion.

The company said its board authorized the repurchase of up to $20 billion of common shares.

Shares of Uber ( UBER ) were down 1.5% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Binah Capital Shares Almost Double in Premarket Activity After Slumping 20% in Previous Regular Trading Session
--Binah Capital Shares Almost Double in Premarket Activity After Slumping 20% in Previous Regular Trading Session
Mar 28, 2024
05:50 AM EDT, 03/28/2024 (MT Newswires) -- Price: 19.16 , Change: +9.34, Percent Change: +98.32 ...
Veon Cancels Revolving Credit Facility After Full Repayment
Veon Cancels Revolving Credit Facility After Full Repayment
Mar 28, 2024
05:55 AM EDT, 03/28/2024 (MT Newswires) -- Veon ( VEON ) said Thursday it has repaid in full its outstanding balance of $805 million on its revolving credit facility and canceled the financing tool. The company said the repayment and cancellation will reduce its interest expenses. Price: 23.95, Change: +0.1, Percent Change: +0.42 ...
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China
Mar 28, 2024
05:47 AM EDT, 03/28/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Wednesday the China National Medical Products Administration has accepted for review its supplemental new drug application for savolitinib as a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. If it is approved, the new label indication for savolitinib will be expanded to...
RH Stock Rises on Expectations for Full-Year Revenue Growth Amid Accelerating Demand Trends
RH Stock Rises on Expectations for Full-Year Revenue Growth Amid Accelerating Demand Trends
Mar 28, 2024
05:55 AM EDT, 03/28/2024 (MT Newswires) -- RH (RH) shares climbed early Thursday as the home furnishing retailer anticipates annual revenue growth in fiscal 2024 with demand trends to accelerate throughout the year, even though it recorded weaker-than-expected fourth-quarter results. The company forecast revenue to increase by 8% to 10% for the current fiscal year, as well as demand growth...
Copyright 2023-2026 - www.financetom.com All Rights Reserved